Bonnie Gillis | Authors


Chemotherapy Safe After Radium-223 for Men With mCRPC

April 19, 2016

The explosion of new drugs for the treatment of castration-resistant prostate cancer (CRPC) is a welcome advance, but raises questions about how best to sequence these drugs with standard docetaxel chemotherapy.

Coordination of Care Based on Patient-Reported Outcomes Improves End-of-Life Care and Lowers Costs

October 19, 2015

Coordinating radiation therapy teams and palliative care teams based on patient reported outcomes from University of Virginia Health System improved outpatient symptom management and decreased end-of-life hospitalizations, as well as costs of care for patients with late-stage cancer.

Tasquinimod Discontinuation in mCRPC Highlights Need for Better Clinical Trial Design

October 02, 2015

Tasquinimod demonstrated promise in phase II trials but failed to improve overall survival in a phase III trial in treatment-naive metastatic castration-resistant prostate cancer; some experts believe this failure highlights the need for more intelligent clinical trial designs in prostate cancer.